Nachrichten zur Cara Therapeutics Aktie

Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a…

Bain Capital Life Sciences Discloses Position in CARA / Cara Therapeutics

A Bain Capital fund has disclosed ownership of 5% of Cara Therapeutics....…

Insiderhandel: President and CEO verkauft Aktien von Cara Therapeutic im Wert von 161.051$

Posner, Christopher - Vorstand - Tag der Transaktion: 2022-11-16...…

Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of -2.38% and 28.91%, respectively, for the quarter ended September 2022. Do the…

Form 8-K Cara Therapeutics, Inc. For: Nov 07

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Cara Therapeutics Reports Third Quarter 2022 Financial Results

– Net revenue was $16.2M for 3Q22 including profit-sharing revenue of $7.4M from KORSUVA® (difelikefalin) injection –...…

Cara Therapeutics Q3 2022 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Cara Therapeutics (CARA) Might Surprise This Earnings Season

Cara Therapeutics (CARA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings…

Cara Therapeutics to Present at Upcoming Investor Conferences

STAMFORD, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a…

Cara Therapeutics (CARA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Cara (CARA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.…

Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022

STAMFORD, Conn., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a…

SWK Holdings unit receives $5M payment from Cara Therapeutics

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Global Legal Cannabis Market Report 2022-2030 Featuring Gw Pharmaceuticals, Aurora, Aphria, Cronos, Tilray, Sundial Growers, Insys Therapeutics, Scotts Co, Vivo Cannabis, & Cara Therapeutics

DUBLIN, Oct. 6, 2022 /PRNewswire/ -- The "Legal Cannabis Market Size, Share & Trends Analysis Report by Source (Marijuana, Hemp),…

Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan

STAMFORD, Conn., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a…

Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a…

Cara Therapeutics hires new finance chief

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Cara Therapeutics Names Ryan Maynard as CFO

Cara Therapeutics Names Ryan Maynard as CFO...…

Form 8-K Cara Therapeutics, Inc. For: Sep 12

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress

– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) –...…

Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

STAMFORD, Conn., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a…

Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022

Presentation will highlight opportunity for oral difelikefalin to address a significant unmet need in the treatment of pruritus in patients…

Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress

Oral presentation will include data from the Phase 2 trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in…

VFMCRP, Cara: Kapruvia Approved In Switzerland To Treat Hemodialysis Patients

BAD HOMBURG VOR DER HOEHE (dpa-AFX) - Vifor Fresenius Medical Care Renal Pharma or VFMCRP and Cara Therapeutics, Inc. (CARA),…

Cara Therapeutics Reports Second Quarter 2022 Financial Results

– Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA™ (difelikefalin) injection and a…

Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022

STAMFORD, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a…

Insiderhandel: Aufsichtsrat verkauft Aktien von Cara Therapeutic im Wert von 65.160$

Bains, Harrison M Jr - Aufsichtsrat - Tag der Transaktion: 2022-07-15...…

Insiderhandel: Aufsichtsrat verkauft Aktien von Cara Therapeutic im Wert von 32.580$

Ives, Jeffrey L. - Aufsichtsrat - Tag der Transaktion: 2022-07-15...…

High Unmet Needs Remain in Nephrology Despite Newly Approved Treatment Options According to Latest Research from Spherix Global Insights

Launch data tracking the market receptivity for Korsuva (Vifor/Cara Therapeutics), Kerendia (Bayer), Lupkynis (Aurinia Pharmaceuticals), and Tarpeyo (Calliditas) unveils gaps…

Form 8-K Cara Therapeutics, Inc. For: Jun 28

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Cara Therapeutics, Inc. For: Jun 02

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Cara Therapeutics stock soars after Q1 earnings beat, optimism over Korsuva U.S. launch

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Cara Therapeutics to Present at May Investor Conferences

STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading…

Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022

STAMFORD, Conn., April 29, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading…

Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

ST. GALLEN, Switzerland and STAMFORD, Conn., April 28, 2022 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma…

Insiderhandel: Chief Scientific Off,SVP-R&D verkauft Aktien von Cara Therapeutics im Wert von 21.247$

Menzaghi, Frederique Ph.d. - Vorstand - Tag der Transaktion: 2022-04-01...…

Insiderhandel: Secy; Chief Compliance & G.C. verkauft Aktien von Cara Therapeutics im Wert von 19.556$

Terrillion, Scott - Vorstand - Tag der Transaktion: 2022-04-01...…

Insiderhandel: President and CEO verkauft Aktien von Cara Therapeutics im Wert von 25.416$

Posner, Christopher - Vorstand - Tag der Transaktion: 2022-04-04...…

Cara Therapeutics (CARA) Investor Presentation - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Cara Therapeutics Korsuva improves itch biomarkers in eczema patients in study

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus

Data presented in late-breaking session at the 2022 American Academy of Dermatology (AAD) Annual Meeting Data presented in late-breaking session…

Taking A (Speculative) Position In Cara Therapeutics

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting

Oral presentation will include biomarker data from KARE Phase 2 clinical trial of Oral KORSUVA™ (difelikefalin) for the treatment of…